University of Leicester nets $3.6M grant for protein drug-target work; pSivida begins PhIII eye implant trial;

> The University of Leicester corralled a £2.4 million ($3.6 million) research funding grant for its work on gene expression that could lead to anti-cancer drugs using protein complexes as drug targets. Report

> pSivida ($PSDV) began a Phase III pivotal trial, the first of two, for its micro-insert designed to treat chronic, non-infectious uveitis affecting the posterior segment of the eye. Release

> Researchers at RMIT in Australia have created nanoparticles called yoctowells that allow for better encapsulation of drugs and controlled release. Story

> Oxford professor Constantin Coussios is looking into the potential of ultrasound as a drug-delivery tool, most particularly for people with vertebrae problems. Article

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.